We evaluated the aspartate transaminase/alanine transaminase (De Ritis) ratio as a predictive biomarker for metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy, using propensity score matching. The ratio was an independent predictor for cancer-specific and overall survival after cytoreductive nephrectomy. This novel biomarker can be used to predict the prognosis of metastatic renal cell carcinoma patients before cytoreductive nephrectomy.Background:
The usefulness of the aspartate transaminase (AST)/alanine transaminase (ALT) ratio (De Ritis ratio) as a predictive biomarker for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN) remains unclear.Patients and Methods:
The data from 118 patients were retrospectively evaluated. The endpoints were cancer-specific survival (CSS) and overall survival (OS) after CN. We compared these according to the AST/ALT ratio before and after 1:1 propensity score matching. The independent predictors for CSS and OS were also analyzed.Results:
The area under the receiver operating characteristic curve was 0.603. The maximum Youden index indicated that the cutoff value for the AST/ALT ratio was 1.24. Before matching, a high AST/ALT ratio was significantly associated with inferior CSS and OS (P < .05 for all). After matching, 34 patients each were allocated to the high and low AST/ALT ratio groups. In the matched cohort, CSS and OS tended to be lower in the high AST/ALT ratio group, although the results were not statistically significant (median CSS, 18.4 months vs. not reached, P = .121; OS, 18.4 months vs. not reached, P = .0957). Furthermore, multivariate analyses revealed that the AST/ALT ratio was an independent predictor for CSS and OS (CSS hazard ratio, 2.17, P = .0472; OS hazard ratio, 2.30, P = .0258).Conclusion:
The preoperative AST/ALT ratio can be an effective predictive biomarker for CSS and OS in patients with mRCC.